Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion
Clearwater Analytics Holdings (NYSE: CWAN) and Enfusion Inc. (NYSE: ENFN) announced a significant milestone in their proposed acquisition deal with the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on February 24, 2025. This development marks the fulfillment of a key closing condition for the transaction.
The acquisition, which combines two leading SaaS-based investment management solution providers, is anticipated to close in the second quarter of 2025. The completion remains subject to customary closing conditions, including obtaining Enfusion shareholder approval.
Clearwater Analytics Holdings (NYSE: CWAN) e Enfusion Inc. (NYSE: ENFN) hanno annunciato un traguardo significativo nel loro accordo di acquisizione proposto con la scadenza del periodo di attesa della Hart-Scott-Rodino Antitrust Improvements Act il 24 febbraio 2025. Questo sviluppo segna il soddisfacimento di una condizione chiave per la chiusura della transazione.
L'acquisizione, che unisce due fornitori leader di soluzioni di gestione degli investimenti basate su SaaS, è prevista per chiudere nel secondo trimestre del 2025. Il completamento rimane soggetto a condizioni di chiusura abituali, inclusa l'approvazione degli azionisti di Enfusion.
Clearwater Analytics Holdings (NYSE: CWAN) y Enfusion Inc. (NYSE: ENFN) anunciaron un hito significativo en su acuerdo de adquisición propuesto con la expiración del período de espera de la Ley Hart-Scott-Rodino de Mejoras Antimonopolio el 24 de febrero de 2025. Este desarrollo marca el cumplimiento de una condición clave para el cierre de la transacción.
La adquisición, que combina a dos proveedores líderes de soluciones de gestión de inversiones basadas en SaaS, se anticipa que se cierre en el segundo trimestre de 2025. La finalización sigue sujeta a condiciones de cierre habituales, incluida la aprobación de los accionistas de Enfusion.
클리어워터 애널리틱스 홀딩스 (NYSE: CWAN)와 엔퓨전 주식회사 (NYSE: ENFN)은 2025년 2월 24일에 하트-스콧-로디노 반독점 개선법의 대기 기간이 만료되면서 제안된 인수 거래에서 중요한 이정표를 발표했습니다. 이 발전은 거래의 주요 마감 조건이 충족되었음을 의미합니다.
이번 인수는 SaaS 기반 투자 관리 솔루션 제공업체 두 곳을 통합하며, 2025년 2분기에 마감될 것으로 예상됩니다. 완료는 엔퓨전 주주의 승인을 포함한 관례적인 마감 조건에 따라 달라집니다.
Clearwater Analytics Holdings (NYSE: CWAN) et Enfusion Inc. (NYSE: ENFN) ont annoncé une étape significative dans leur projet d'acquisition avec l'expiration de la période d'attente de la loi Hart-Scott-Rodino sur les améliorations antitrust le 24 février 2025. Ce développement marque l'accomplissement d'une condition clé pour la clôture de la transaction.
L'acquisition, qui combine deux fournisseurs leaders de solutions de gestion d'investissements basées sur SaaS, devrait se conclure au deuxième trimestre de 2025. L'achèvement reste soumis à des conditions de clôture habituelles, y compris l'approbation des actionnaires d'Enfusion.
Clearwater Analytics Holdings (NYSE: CWAN) und Enfusion Inc. (NYSE: ENFN) haben einen bedeutenden Meilenstein in ihrem vorgeschlagenen Übernahmegeschäft bekannt gegeben, da am 24. Februar 2025 die Wartefrist des Hart-Scott-Rodino Antitrust Improvements Act abläuft. Diese Entwicklung markiert die Erfüllung einer wichtigen Abschlussbedingung für die Transaktion.
Die Übernahme, die zwei führende Anbieter von SaaS-basierten Investmentmanagementlösungen kombiniert, wird voraussichtlich im zweiten Quartal 2025 abgeschlossen. Der Abschluss bleibt an übliche Abschlussbedingungen gebunden, einschließlich der Genehmigung der Aktionäre von Enfusion.
- Antitrust regulatory approval achieved through HSR Act waiting period expiration
- Merger combines two complementary SaaS investment management solution providers
- Transaction progressing on schedule towards Q2 2025 closing
- Deal completion still contingent on Enfusion shareholder approval
Insights
The expiration of the Hart-Scott-Rodino waiting period marks a critical milestone in Clearwater Analytics' acquisition of Enfusion, removing a significant regulatory hurdle and increasing the probability of deal completion. With Enfusion shareholder approval now the primary remaining condition, the transaction appears on track for its Q2 2025 closing target.
This acquisition represents a strategic expansion of Clearwater's capabilities in the investment management software ecosystem. Enfusion's front-to-back office platform, particularly strong in portfolio management and order execution for hedge funds, complements Clearwater's strength in investment accounting, reporting, and analytics. The combined entity would offer a more comprehensive solution spanning the investment lifecycle, potentially capturing greater wallet share from existing clients while expanding into new market segments.
For Clearwater investors, this deal advances the company's expansion strategy beyond its traditional middle and back-office focus into front-office capabilities. The acquisition should accelerate Clearwater's growth trajectory by tapping into Enfusion's established hedge fund client base while providing cross-selling opportunities. Additionally, the transaction strengthens Clearwater's competitive position against both legacy providers and newer fintech entrants in the increasingly cloud-native investment management software market.
The regulatory clearance suggests antitrust authorities see sufficient competition remaining in the market despite this consolidation. However, Enfusion shareholders will still need to evaluate whether the offer adequately values the company's growth potential as a standalone entity versus the benefits of joining Clearwater's larger platform. The market's positive reaction to the regulatory approval indicates investors see value in the strategic combination of these complementary businesses.
The expiration of the waiting period under the HSR Act satisfies one of the closing conditions for the completion of the transaction.
The transaction is expected to close in the second quarter of 2025, subject to the satisfaction or waiver of customary closing conditions including the receipt of Enfusion shareholder approval.
About Clearwater Analytics
Clearwater Analytics (NYSE: CWAN), a global, industry-leading SaaS solution, automates the entire investment lifecycle. With a single instance, multi-tenant architecture, Clearwater offers award-winning investment portfolio planning, performance reporting, data aggregation, reconciliation, accounting, compliance, risk, and order management. Each day, leading insurers, asset managers, corporations, and governments use Clearwater’s trusted data to drive efficient, scalable investing on more than
About Enfusion
Enfusion’s investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration boosting agility and powering growth. Enfusion partners with over 850 investment managers from 9 global offices spanning four continents. For more information, please visit www.enfusion.com.
Use of Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the beliefs and assumptions of Clearwater’s and Enfusion’s management and on information currently available to them. Forward-looking statements include information concerning the following factors in reference to Clearwater and/or Enfusion: the timing of the consummation of the acquisition and the ability to satisfy closing conditions, possible or assumed future results of operations, possible or assumed performance, business strategies, technology developments, financing and investment plans, competitive position, industry, economic and regulatory environment, potential growth opportunities and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” or similar expressions and the negatives of those terms, but are not the exclusive means of identifying such statements.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond Clearwater’s and Enfusion’s control, that may cause their actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the ability to successfully close the acquisition, Clearwater’s ability to successfully integrate the operations and technology of Enfusion with those of Clearwater, retain and incentivize the employees of Enfusion following the close of the acquisition, retain Enfusion’s clients, repay debt to be incurred in connection with the Enfusion acquisition and meet financial covenants to be imposed in connection with such debt, risks that cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected, as well as other risks and uncertainties discussed under “Risk Factors” in Clearwater’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the US Securities and Exchange Commission (the “SEC”) on February 26, 2025 and in Enfusion’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 12, 2024, those discussed under “Risk Factors” in Enfusion’s Annual Report on Form 10-K for the year ended December 31, 2024 that will be filed following this press release, as well as in other periodic reports filed by Clearwater and Enfusion with the SEC. These filings are available at www.sec.gov and on Clearwater’s website, investors.clearwateranalytics.com, and Enfusion’s website, ir.enfusion.com. Given these uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing Clearwater’s or Enfusion’s expectations or beliefs as of any date subsequent to the time they are made. Each of Clearwater and Enfusion does not undertake to and specifically declines any obligation to update any forward-looking statements that may be made from time to time by or on behalf of Clearwater or Enfusion.
No Offer or Solicitation
This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”).
Additional Information and Where to Find It
In connection with the acquisition, Clearwater has filed with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the shares of Clearwater’s common stock to be issued pursuant to the acquisition, which constitutes a prospectus of Clearwater and a proxy statement of Enfusion (the “proxy statement/prospectus”). Each of Clearwater and Enfusion may also file other documents with the SEC regarding the acquisition. This press release is not a substitute for the Registration Statement, proxy statement/prospectus or any other document which Clearwater or Enfusion may file with the SEC in connection with the acquisition. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION, THE RISKS RELATED THERETO, AND RELATED MATTERS. After the Registration Statement has been declared effective, the definitive proxy statement/prospectus (if and when available) will be mailed to Enfusion’s security holders. Investors and security holders will be able to obtain free copies of the Registration Statement and proxy statement/prospectus, as each may be amended or supplemented from time to time, and other relevant documents filed by Clearwater and Enfusion with the SEC (if and when available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by Clearwater, including the proxy statement/prospectus will be available free of charge from Clearwater’s website at investors.clearwateranalytics.com/overview. Copies of documents filed with the SEC by Enfusion, including the proxy statement/prospectus will be available free of charge from Enfusion’s website at ir.enfusion.com.
Participants in the Solicitation
Clearwater, Enfusion and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the Transaction. Information about Clearwater’s directors and executive officers is available in Clearwater’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 26, 2025, its definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 29, 2024, and in the proxy statement/prospectus. Information about the directors and executive officers of Enfusion is available in its Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 12, 2024, its Annual Report on Form 10-K for the year ended December 31, 2024 that will be filed following this press release, its definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 26, 2024, and in the proxy statement/prospectus. Other information regarding the participants in the solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are or will be contained in the Registration Statement, the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the Transaction when they become available. Investors should read the proxy statement/prospectus carefully before making any voting or investment decisions. Copies of the documents filed with the SEC by Clearwater and Enfusion will be available free of charge through the website maintained by the SEC at www.sec.gov. Additionally, copies of documents filed with the SEC by Clearwater, including the proxy statement/prospectus will be available free of charge from Clearwater’s website at investors.clearwateranalytics.com/overview, and copies of documents filed with the SEC by Enfusion, including the proxy statement/prospectus will be available free of charge from Enfusion’s website at ir.enfusion.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226851041/en/
Investor Contact for Clearwater Analytics
Joon Park | +1 415-906-9242 | investors@clearwateranalytics.com
Investor Contact for Enfusion
Bill Wright | investors@enfusion.com
Media Contact for Clearwater Analytics
Claudia Cahill | +1 703-728-1221 | press@clearwateranalytics.com
Media Contact for Enfusion
Mollie Applegate | media@enfusion.com
Source: Clearwater Analytics Holdings, Inc.
FAQ
When is the Clearwater Analytics (CWAN) acquisition of Enfusion expected to close?
What regulatory milestone did CWAN's acquisition of Enfusion clear in February 2025?
What conditions remain for CWAN to complete the Enfusion acquisition?
What type of companies are involved in the CWAN-Enfusion merger?
